GLASGOW, Scotland, July 17, 2023 (GLOBE NEWSWIRE) -- EnteroBiotix Limited (“EBX”), a clinical stage company with the premier platform for full-spectrum microbiome therapeutics, today announced the ...

GLASGOW, Scotland, Feb. 01, 2024 (GLOBE NEWSWIRE) -- EnteroBiotix Limited (“EBX”), a clinical stage biopharmaceutical company with the premier platform for full-spectrum microbiome therapeutics, today ...

Glasgow, Scotland – 28 April 2025. EnteroBiotix Limited (‘EnteroBiotix’), a biopharmaceutical company developing best-in-class therapies for gut health, today announced that data from its Phase 2a ...

EBX-102 was well tolerated and showed multiple positive trends over placebo Findings support progression to a Phase 2b trial Glasgow, Scotland – 13 May 2025. EnteroBiotix Limited (‘EnteroBiotix)’ a ...

Glasgow, Scotland - 2 May 2025. EnteroBiotix Limited ('EnteroBiotix'), a clinical-stage biopharmaceutical company focussed on developing best-in-class drugs for gut health, today announced that ...

EBX-102 demonstrated proof-of-principle across multiple microbiome assessments, inflammatory biomarkers and clinical assessments, supporting its continued development as the first microbial therapy ...

ABERDEEN, Scotland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--EnteroBiotix, a leading clinical stage microbiome therapeutics company headquartered in Aberdeen, Scotland, today announced that it has secured ...

122 patients with moderate to severe irritable bowel syndrome (IBS) were recruited to EnteroBiotix’s Phase 2 TrIuMPH trial assessing EBX-102-02 EnteroBiotix completed enrolment ahead of its planned ...

ABERDEEN, Scotland--(BUSINESS WIRE)--EnteroBiotix, a leading clinical stage microbiome therapeutics company, has been granted a manufacturers ‘specials’ license from the Medicines and Healthcare ...

EnteroBiotix has rounded up $21.5 million in a series A financing to advance a pipeline of drugs targeting the microbiome, which is believed to play a role in overall health. With the capital, the ...

EnteroBiotix Limited (EnteroBiotix), a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics, announced the completion of recruitment in its ...